Method for prediction of recurrent cervical cancer |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
IPC classes for russian patent Method for prediction of recurrent cervical cancer (RU 2485523):
 Method for aromatase activity test / 2481587
Blood serum is examined for lutropin, follitropin, oestradiol, total testosterone and free testosterone levels before and 48 hours after the oral administration of 450 aromatase inhibitor, letrozole 10 mg, and the variations of lutropin and follitropin, as well as of the oestradiol/total testosterone and oestradiol/free testosterone relations are used to asses aromatase activity in points assigned by a certain way to consider low aromatase activity shown by total score 0 to 7 points, normal aromatase activity - 8 to 14 points, and high aromatase activity - 15 points or more.
Method for specifying directionality of pathological process in mucinous gastric carcinoma / 2480771
In males with mucinous gastric carcinoma after a curative resection to the extent of gastrectomy, tumor tissue is analysed for the level of testosterone. If the tissue value is 7.8±0.6 ng/g, process generalisation within 6 to 12 months is predicted; the level of tissue testosterone 174.5±15.6 ng/g enables predicting the favourable clinical course of the process, prolongation of the patient's life.
Method for prediction of recurrent endometrial polyps in postmenopausal women / 2478959
Transvaginal echography in the patients suffering endometrial polyps is conducted to measure an M-echo thickness, mm, the presence of obesity (Ob), blood follicle-stimulating hormone (FSH), IU/l, oestradiol (E2), pg/l; an insulin-resistance index is calculated by HOMA technique; a therapeutic strategy (ThStra) is taken into consideration; a probability of developing recurrent endometrial polyps (p) 1 year after the operation is determined by formula. If the probability exceeds 0.7, a high risk of recurrence is predicted. The probability falling within the range of 0.5 to 0.7 shows a moderate risk, while the probability of 0 to 0.5 shows a low risk.
Diagnostic technique for extraintestinal manifestations of celiac disease / 2476892
Blood serum is examined for prolactin and folic acid, and if the prolactin level is 30.6 ng/ml and more, while the folic acid level is 8.7 ng/ml and lower, the extraintestinal manifestations of celiac disease are diagnosed.
 Method for steroid profiling in dope test of sportsmen / 2467331
Invention refers to medicine, namely sports medicine, and may be used for steroid profiling in dope test of sportsmen. That is ensured by urine sample hydrolysis by a mixture of two enzymes: β-glucuronidase E.coli and arylsulphatase H.pomatia in volume ratio 1:1 to 1:3 in the presence of a citrated buffer solution and an internal standard. The hydrolysate is separated, derivatised that is followed by chromatic/mass-spectral analysis of the sample and recording of the derived results and stating the presence of endogenic steroids (ES). The ES value is determined in a sportsman for at least 10-15 times every 10-12 days. The analysis results are used to set minimum and maximum values of each of the derived ES. Said values are accepted to be a confidence range, and a steroid profile of the sportsman is drawn as a set of confidence ranges of all found ES.
Method of determining clinical effectiveness in cervical cancer / 2464576
One week after the termination of polychemotherapy, daily urine is examined for the amount of cortisol and cortisone, while blood is examined for adrenocorticotropic hormone. It is followed by calculating the relation of total cortisol and cortisone to adrenocorticotropic hormone. If the derived value is 0.74 and higher, high responsiveness to chemopreparations is stated.
Method for describing nature of arrested sexual development in boys in puberty with growth retardation / 2462720
Examination results are used to detect boys with the absence or insufficiency of blood concentrations of at least two of three hormones (luteinising hormone, follicle-stimulating hormone, total testosterone) to be used for the clinical course of transcranial magnetic therapy. The concentration of all hormones are evaluated in 1-1.5 months, and if observing increase of the concentrations of at least two hormones, including testosterone by min. 25% from the initial values, a functional nature of arrested sexual development is stated. If observing no increase or increase of the concentrations of two hormones, including testosterone by max. 25% from the initial values, an organic nature of arrested sexual development is stated.
 Diagnostic technique for idiopathic nasal breathing irregularities in pregnant women / 2456604
Blood serum of a pregnant woman is examined for the oestradiol concentration by enzyme-linked immunosorbent assay. Observing the oestradiol concentrations exceeding normal values according to weeks of gestation in 1.4 times and more enables stating idiopathic nasal breathing irregularities accompanying a period of pregnancy.
Method for prediction of level of efficiency of reduction of manifestation severity of atopic dermatitis / 2453851
Pre-therapy blood plasma is analysed for immunoglobulin E, adrenocorticotrophin and endorphin, the index SCORAD dynamics is determined by formula: Dsk=1.34147-0.000820741*IgE-0.00382642*ACTP+0.0209401*endorphin wherein IgE is the level of acute blood plasma immunoglobulin E mIU/ml; ACTP is the level of acute blood plasma adrenocorticotrophin ng/l. If observing the Dsk value exceeding 1.18, a prognosis of improving clinical dynamics of recovery is favourable; the conventional therapy is considered to be sufficient. The Dsk value being equal to 1.18 or less, the improving clinical dynamics of recovery is unfavourable, the intensified therapeutic scheme for atopic dermatitis is considered to be preferential.
 Method for identification and classification of 3-oxosteroids and their metabolites in doping test of sportsmen / 2452967
Blood plasma is examined for the presence and the position of double bonds and the related differences in structural characteristics. Common and examined steroids are chemically modified by a carboxyl group (oximes); their mass spectra are read out and recorded; characteristic ions (lc) and neutral loss (Do) are specified in the mass spectra. The specified lc and Do values are related to those specific for common 3-oxosteroid oximes by the absolute value. Herewith it is only the similar lc and Do values from both sides differing by 0.3% and less that are taken into consideration; the comparison results are used to identify 3-oxosteroid oximes.
 Annexin a3 autoimmune regulation of prostate cancer / 2484482
Diagnostic technique for prostate cancer involves detecting the subcellular distribution of annexin A3 in a biological sample, and wherein if the apical intracellular localisation of annexin A3 is detected, a benign growth or pre-cancer is diagnosed, and the diffuse intracellular localisation of annexin A3 enables diagnosing a malignancy. The diagnostic technique for prostate cancer may also involve detecting in a sample the presence and/or the count of anti-annexin A3 autoantibodies, and optionally the presence and/or the count of regulatory T-cells, wherein the presence of the ANXA3 autoantibodies and/or the presence of significant amounts of intracellular ANXA3-positive, other than apical regulatory T-cells testifies to the malignancy. The group of inventions also concerns an analytical reagent for diagnosing prostate cancer, a method of updating the diagnosis in an individual related to an intermediate risk group of prostate cancer.
 Optimising individual doses of 5-fluoruracil in folfox regime / 2482496
Invention describes a method of gradually optimising a dose of 5-FU administered by continuous infusion to the patients being treated with the FOLFOX or similar regime, on the basis of the plasma concentration of 5-FU measured during the preceding continuous infusion of 5-FU, and described in the given application of the decision procedure. The present invention also refers to a method of treating a patient with cancer wherein the dose of 5-FU administered into continuous infusion in each FOLFOX cycle or similar therapeutic cycle, optimised with using the decision procedure in accordance with the invention.
 Differential diagnostic technique for leiomyosarcoma uteri and proliferating (cell) leiomyomata / 2481585
What is presented is a differential diagnosis technique for leiomyosarcomas uteri and proliferating (cell) leiomyomatas involving the analysis of molecular genetic variations of microsatellite DNA samples of tumour tissue. The genetic variations of the D17S1161, D10S1213, D10S1146, D10S218, D10S24, D9S942, D9S251 and D3S1295 microsatellites are to be found in the sample of tumour and surrounding normal tissue or peripheral venous blood by polymerase chain reaction (PCR) using specific primers. If observing some variations represented by heterozygosis loss and/or microsatellite instability in at least one of these microsatellites in the sample of tumour tissue, the malignancy is diagnosed.
 Use of melanoma inhibitory activity (mia) protein as early indicator for therapeutic response in melanoma / 2480769
First concentration of the melanoma inhibitory activity (MIA) protein in a first biological sample taken from a mammalian patient prior to the treatment, and a second concentration of MIA in the second biological sample taken from the mammalian patient after the beginning of treatment. Then, the first and second concentrations of MIA are compared, and if the second concentration of MIA appears to be decreased as compared to the first concentration of MIA, a positive response to treatment manifested in downsizing the tumour is stated.
 Pharmaceutical composition containing ahtm-cd6 monoclonal antibody, applicable for diagnosing and treating rheumatoid arthritis / 2472526
Group of inventions refers to medicine, namely immunology and may be used for treating rheumatoid arthritis. That is ensured by the use of a pharmaceutical composition containing an active principle presented by a monoclonal antibody which recognises a CD6 human leukocyte differentiation antigen and produced by secreting hybridoma IOR-TIA with deposition No. ECACC 96112640, and an applicable excipient. What is also presented is a method for the use of the pharmaceutical composition in the form of injections, as well as the use of a monoclonal antibody which recognises the CD6 human leukocyte differentiation antigen, for preparing a therapeutic agent.
 Method for estimating risk of progressing non-small-cell lung cancer following surgical management / 2472161
What is presented is a method for estimating a risk of progressing non-small-cell lung cancer (NSCLC) in the patients following surgical management. The amount of IgG autologous antobidies to native secretory mucin MUCl (anti-sMUCl AAT) in blood serum in the NSCLC patients before the surgical managements, 9-14 days after the operation and during the follow-up care. The anti-sMUCl AAT level in patient's blood serum is matched with a double value described by formula Nmax=X+a, wherein Nmax is an upper limit of distribution, X is an average level of anti-sMUCl AAT, a is 95% confidence range of distribution of the level of anti-sMUCl AAT in healthy donors. The unchanged initially high level of anti-sMUCl AAT (more than 2Nmax) or the increased initially low level of anti-sMUCl AAT (less than 2Nmax) to the value ≥ 2Nmax after the surgical operation is a prognostic of non-recurrent clinical course. The unchanged initially low level of anti-sMUCl AAT (less than 2Nmax) after the operation testifies to the presence of latent tumour centres or latent tumour dissemination.
 Differential diagnostic technique for prostate cancer / 2469333
What is presented is a differential diagnostic technique for prostate cancer involving blood chromatography analysis. Plasminogen isoforms are recovered from blood plasma by affine chromatography by modified Merz method. A spectrum of plasminogen isoforms are evaluated by two-dimensional electrophoresis in polyacrylamide gel. If observing plasminogen isoforms of molecular weight 112 kDa and isoelectric point 7.71 (P13), 7.73 (P14) or 7.78 (P15) or their combination, prostate malignancy is diagnosed. if observing plasminogen isoform of molecular weight 112 kDa and isoelectric point 7.85 (P16) and/or 7.71 (P13), if having no isoform of molecular weight 112 kDa and isoelectric point 7.68 (P12), advanced (disseminated) stage of development is diagnosed.
 Annexin a3 monoclonal antibodies for detection of prostate carcinoma / 2467335
Invention refers to medicine, and concerns a diagnostic technique for prostate cancer involving sample analysis for the presence and/or the amount of annexin A3 with using a monoclonal antibody specific to annexin A3 of low cross reactivity to the other annexins and aiming at an N-terminal of annexin A3, especially on an epitope in the region of amino acid of 1-16 human annexin A3. Also, the invention refers to a reagent for diagnosing prostate cancer containing such antibodies.
Method of determining clinical effectiveness in cervical cancer / 2464576
One week after the termination of polychemotherapy, daily urine is examined for the amount of cortisol and cortisone, while blood is examined for adrenocorticotropic hormone. It is followed by calculating the relation of total cortisol and cortisone to adrenocorticotropic hormone. If the derived value is 0.74 and higher, high responsiveness to chemopreparations is stated.
Diagnostic technique for prostate cancer / 2464574
Digital rectal examination is applied to localise a prostate induration (INp). If observing the prostate induration, the value equal to 1 is assigned to the value INp, while the absence of the induration shows the value equal to 0. The ultrasonic data are used to measure prostate volume (Vp), cm3. Patient's blood serum is examined for a level of total prostate-specific antigen (Ltpsa), ng/ml. Additionally, the primary histologic findings (PHF) of the prostate biopsy materials are studied. If observing high-grade prostatic intraepithelial neoplasia (PIN) as shown by the primary histologic findings of the prostate biopsy materials, the value equal to 1 is assigned to the PHF; while low-grade PIN or the absence thereof enables assigning the value equal to 0. The diagnostic coefficient (Cd) is calculated by formula: Cd=9.01-9.62 (INp)-0.015 (Vp)-0.27 (PHF)-9.51 [(Ltpsa):(Vp)]. The value Cd<0 enables diagnosing prostate cancer in the patients with the cancer-negative primary histologic findings.
Method for specifying therapeutic approach to children suffering gastroesophageal reflux disease / 2479845
What is considered is child's urine 6-sulphatoxymelatonine, and if the derived value appears to exceed 41.0 ng/ml, the standard therapeutic course is stated to be inadequate and to be prolonged by prescribing melatonine, and essential surgical management is regarded.
|
FIELD: medicine. SUBSTANCE: method for prediction of recurrent cervical cancer involves biochemical daily urine analysis to determine daily urine androsterone and etiocholanolone to be related; if the relation is 0.75 mg/day or less, the recurrent disease is predicted for the first 2 years, and if the relation exceeding 0.75 mg/day, a prolonged recurrence-free period up to 10 years or more is predicted. EFFECT: method enables the early, preclinical detection of the recurrent disease, as well as an individual selection of therapeutic approaches to each patient. 2 tbl
The invention relates to medicine, namely to biochemical research in Oncology, and can be used for planning of methods of prevention and treatment of recurrent cervical cancer (cervical cancer) as soon as possible after the end of the complex/combined treatment of cervical cancer patients. It is known that the prognostic value special treatment of cancer of cervical stump is an ultrasound examination, supplemented by Doppler examination showing effective treatment reducing the number of pathological loci in the area of the tumor to 1-2 against 5-10 before treatment, the disappearance of signs of venous congestion and dilation of blood vessels. Reducing the flow velocity is almost 2 times, lowering 31.4 index of vascular resistance and by 57.1 pulsating index (Poryvaev Y.A. author. Kida. Diss. "Autohemotherapy in treatment of cancer of the cervical stump", Rostov-on-don, 2006). However, when listing multiple prognostic factors, firstly, does not specify which of them are major, which in forecasting the future course of the disease should be guided first and foremost, and secondly, not individualized factors such forecast, as an index of vascular resistance and pulsatory index is not specified the size of their variables and, that makes it impossible for the practical use of these indicators to predict the course of disease after completion of cancer treatment. There is a method of predicting recurrence of cervical cancer (patent RF №2023266, publ. 15.11.94,, bull. 21), chosen as a prototype, including the determination of prolactin in the serum of patients before treatment. When the value of its concentration in excess of the 400 µa/ml, predict recurrence of vulvar cancer in the near future. However, this method has drawbacks, namely to predict the risk of recurrence of the disease requires special equipment, special conditions for radioimmunoassay analysis, expensive test kits RIA, serial execution mode of study for which you want a long period of time. Thus, presents a method for predicting although quite effective, but difficult to execute, in addition, it is used to predict recurrence only vulvar cancer, which limits its use in other malignant process. The aim of the invention is the early preclinical prevention of recurrence of cervical cancer to develop and apply after comprehensive treatment of additional methods antitumor impacts the via. This objective is achieved in that the admission of the patient to the hospital collected per day urine define conventional biochemical method two hormones: Androsterone and etiocholanolone, calculate the ratio between them in the form of a ratio of Androsterone/etiocholanolone, when the magnitude of the coefficient is 0.75 mg/day or lower, fluctuating between 0.5 to 0.75) predict the likelihood of recurrence of the disease in the first 2 years, and with a value in excess of 0.75 mg/day (fluctuations from 0.9 to 2.8), the duration of remission for over 10 years. A method for predicting recurrence of cervical cancer according to the invention is new, as the ratio of Androsterone/etiocholanolone was not used in Oncology for prediction of recurrence of the disease. The novelty of the invention lies in the fact that when entering the patient cervical cancer in urine collected per day, determine the conventional biochemical method two hormones: Androsterone and etiocholanolone, calculate the magnitude of their correlation (coefficient), when the value of the coefficient of more than 0.75 expect more radical treatment. Androstene and etiocholanolone are androgenic hormones. The Androsterone is Retrospectively compared the long-term results of treatment with the initial value of the coefficient androstene/etiocholanolone in 2 groups of cervical cancer patients (all treated 26 patients). 1 group (15 people) - the duration of recurrence-free period of more than 10 years; 2 group (11 persons) - the duration of recurrence-free period of less than 2 years. The data are given in tables 1 and 2.
A method for predicting the risk of recurrence of cervical cancer, including biochemical analysis of daily urine of the patient, characterized in that in daily urine determine androstene and etiocholanolone, calculate the ratio between them and when the ratio is 0.75 mg/day and below - predict the relapse of the disease in the first 2 years, and with a value in excess of 0.75 mg/day, a long disease-free period of up to 10 years and Bo is her.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
connection, etiocholanolone - 5β-connection. First depress the intensity of the formation of estrogens, which are stimulating FA the torus malignant growth in tissues of the cervix. This reaction determines the possibility of using the ratio of Androsterone/etiocholanolone with prognostic purpose of providing the probability of early recurrence of the disease.